Finance

Lists
ARQT:NASDAQ
Arcutis Biotherapeutics Inc
25,15 $
-0,04%
(-0,010) 1D
25,25 $
+0,40% (+0,10)
After hours
Closed: 5 қаз., 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARQT...
Open
25,09 $
High
25,38 $
Low
24,69 $
Mkt. cap
3,16 млрд
Avg. vol.
2,90 млн
Volume
257,00
P/E ratio
117,24
52-wk high
31,77 $
52-wk low
19,30 $
EPS
0,21 $
Beta
1,57
Shares outstanding
125,69 млн
No. of employees
354
Open
25,09 $
High
25,38 $
Low
24,69 $
Mkt. cap
3,16 млрд
Avg. vol.
2,90 млн
Volume
257,00
P/E ratio
117,24
52-wk high
31,77 $
52-wk low
19,30 $
EPS
0,21 $
Beta
1,57
Shares outstanding
125,69 млн
No. of employees
354
News stories
From web sources and news partners
About Arcutis Biotherapeutics Inc
CEOFrank Watanabe
Employees354
Founded2016
HeadquartersWestlake Village, Калифорния, Америка Құрама Штаттары
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to ARQT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ARQT in the last 3 months.
Highest
Current 25,15 $
40,00 $ (+59,05%)
Average
36,67 $ (+45,81%)
Lowest
34,00 $ (+35,19%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
34,00 $
+35,2%
08/10/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
38,00 $
+51,1%
08/06/2026
Serge Belanger
Needham
Buy
Reiterated
40,00 $
+59%
08/06/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
38,00 $
+51,1%
08/05/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
35,00 $
+39,2%
08/05/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
36,00 $
+43,1%
08/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
35,00 $
+39,2%
07/16/2026
Unknown Analyst
Jefferies
Buy
Maintained
35,00 $
+39,2%
07/09/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
33,00 $
+31,2%
02/27/2026
Last report
2026 ж. 05 там.
Fiscal period
Q2 2026
EPS / Est. (USD)
0,11 $ / 0,05 $
+120,00%beat
Revenue / Est. (USD)
129,86 млн / 118,85 млн
+9,26%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
99,22 млн
129,50 млн
105,40 млн
129,86 млн
Cost of goods sold
8,68 млн
11,69 млн
9,78 млн
10,94 млн
Cost of revenue
8,68 млн
11,69 млн
9,78 млн
10,94 млн
Research and development expenses
19,60 млн
20,45 млн
30,63 млн
20,36 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
62,40 млн
78,98 млн
74,08 млн
82,14 млн
Operating expense
82,01 млн
99,43 млн
104,70 млн
102,49 млн
Total operating expenses
90,69 млн
111,12 млн
114,49 млн
113,43 млн
Operating income
8,53 млн
18,39 млн
-9,09 млн
16,43 млн
Other non operating income
-
443,00 м.
-20,00 мың
-157,00 м.
EBT including unusual items
7,49 млн
17,86 млн
-11,20 млн
15,14 млн
EBT excluding unusual items
7,49 млн
17,86 млн
-11,20 млн
15,14 млн
Income tax expense
80,00 мың
470,00 м.
93,00 мың
136,00 м.
Effective tax rate
1,07%
2,63%
-0,83%
0,90%
Other operating expenses
-
-
-
-
Net income
7,41 млн
17,40 млн
-11,30 млн
15,01 млн
Net profit margin
7,47%
13,43%
-10,72%
11,56%
Earnings per share
0,06
0,13
-0,09
0,11
Interest and investment income
2,04 млн
2,04 млн
2,28 млн
2,28 млн
Interest expense
-3,07 млн
-3,00 млн
-4,37 млн
-3,41 млн
Net interest expenses
-1,04 млн
-965,00 м.
-2,09 млн
-1,13 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
9,09 млн
18,95 млн
-8,53 млн
16,99 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары